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Abstract The optimal management of rectal cancer is
achieved through a shared multidisciplinary decision making
process with accurate staging by imaging being critical for
treatment planning. Good quality, high-resolution MRI has
become the imaging gold standard as it allows consistent stag-
ing and stratification of patients into distinct prognostic
groups according to MR-findings. Imaging features other than
T and N have been proven to influence patient outcomes, and
increasingly these features are taken into consideration when
determining treatment options: distance of tumour to the po-
tential circumferential margin (CRM), presence of tumour
within the extramural rectal vessels (EMVI), discontinuous
tumour deposits (N1c), relationship to the intersphincteric
plane in low rectal tumours and to pelvic compartments in
advanced disease. The presence or absence of proven adverse
MR features should be included in the MRI report and shared
with the patient when treatment choices are offered. MRI en-
ables the identification of high risk tumours where the use of
neoadjuvant therapy is justified and is a robust method of
identifying patients with a strong likelihood of complete re-
sponse after preoperative treatment.
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Introduction
Imaging plays a major role in treatment decision making of
rectal cancer patients. The concept of tumour-spread assess-
ment has markedly changed during the last decade. Rather
than just T and N stage, other imaging prognostic factors
and imaging-based assessment of the surgical planes can help
the colorectal teams make decisions to improve outcomes
(key MR imaging features are listed in the Table 1).
Type of surgery to be performed mainly depends on an
accurate assessment of the local extent of tumour. Screening
programmes are currently identifying more early rectal tu-
mours and potentially benign polyps. However, in up to
30 %, these appear to be more aggressive on final histology
after local excision [1]. When selecting patients for local ex-
cision surgery the purpose of staging is not just to exclude the
presence of malignant lymph nodes but also to assess the
depth of invasion and the degree of preserved submucosa
and muscularis propria to enable a definitive excision proce-
dure to be undertakenwithout the risk of an involved resection
margin.
For locally advanced rectal cancers, preoperative chemora-
diotherapy (CRT) is a standard of treatment. The term ‘locally
advanced’ and its definition varies between centres and coun-
tries. The avoidance of preoperative therapy in patients with a
low risk of local recurrence or distant failure is gaining wide-
spread acceptance in Europe but is based on outcome data that
relates to audited surgical total mesorectal excision (TME)
with removal of tumour and draining nodes in a single
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‘package’. There is also widespread agreement that regardless
of T and N stage, tumour extending to within 1 mm of the
surgical TME plane (mesorectal fascia and intersphincteric
plane) is associated with a high risk of local recurrence.
Such patients are accurately identified by MRI and offered
preoperative chemoradiotherapy [2–4]. MRI findings of pos-
itive extramural venous invasion (EMVI) status, presence of
mucin component within the tumour and invasion of the
intersphincteric space in low rectal tumour are also proven
risk factors for poor outcome [5••, 6]. In primary rectal cancer
patients with TME planes involved, long-term results are bet-
ter if radical exenteration surgery is applied in the first instance
[7, 8] compared to those receiving exenteration for recurrent
disease [9, 10]. Therefore, imaging is needed for defining
surgical planes and identifying necessity of preoperative treat-
ment rather than just assessing tumour spread by TNM
classification.
Stage-directed treatment plan based on pretreatment stag-
ing of rectal cancer is recommended by the National
Comprehensive Cancer Network (NCCN) guidelines [4].
Clinical trials are underway to determine whether reassess-
ment of the tumour after preoperative CRT by high resolution
MRI enables a change of surgical planes in rectal cancer pa-
tients. Formal assessment of shrinkage and downstage of the
primary tumour is needed to determine if an altered strategy
following treatment is safe and improves sphincter preserva-
tion rates (TRIGGER: EudraCT Number 2015-003009-40).
Approximately 30 % of patients show complete response on
final pathology and theoretically could have had their surgery
omitted—thus the role of imaging in identifying such patients
following completion of chemoradiotherapy is also being
evaluated in a randomised clinical trial (EudraCT Number
2015-003009-40) [11]. Currently centres use assessment by
sigmoidoscopy/endoscopy but lack sensitivity in finding pa-
tients with complete response; therefore, new ways of differ-
entiating changes within a treated tumour, throughMRI would
enable the possibility of organ preservation in many more
patients than currently achieved [12].
Prognostically Important Imaging Biomarkers
Extent of Rectal Tumour Within the Mesorectum
(T3a-T3d)
The depth of spread beyond the muscularis in millimetres has
been proven to influence survival rates and is considered as an
important prognostic factor that enables precise prognostic
stratification within the T3 subcategory [13, 14]. Based on
the Erlangen registry of 853 patients it has been shown to
influence on a 5-year cancer specific survival [15, 16]. In
1993, Professor Hermanek of the Erlangen study group pro-
posed dividing T3 stage into four sub-categories: T3a—
spread beyond muscularis propria (MP) no greater than
Table 1 A list of important MR
imaging features Imaging criterion Key points
Extramural tumour spread
(Fig. 1a)
For both colon and rectal cancer, extend of tumour spread beyond the
muscularis propria should be measured (in mm) at the level of advanced
invasion border and staged as <1 mm (T3a), 1–5 mm (T3b), 5–15 mm (T3c)
and >15 mm (T3d).
mrCRM (Fig. 1b) Minimal tumour distance to the TME plane (mrCRM) should be measured; if
clearance is less than 1 mm then the potential TME plane CRM is considered
involved.
Lymph nodes/vascular de-
posits (Fig. 1c)
Seems to be of no prognostic importance for local recurrence; N1c (tumour/
vascular deposits) is of more concern and linked with extramural vascular
invasion.
mrEMVI (Fig. 1c) Large vein extramural vascular invasion should be reported on both pre- and
post-CRT scans and feedback to pathologists to aid their assessment of the
specimen.
Mucinous tumours (Fig. 1d) Mucin component is readily identified on high-resolution MRIs. MR evidence
of mucin within the tumour should be reported.
Tumour response assessment
(Fig. 1e, f)
No uniform threshold for MR RECIST and volumetric analysis. mrTRG is
proven to be an independent prognostic factor. It is reproducible and enables to
identify complete responders. No validated data concerning the added value of
DWI or PET/CT.
Early rectal cancer (Fig. 1g) High-resolution MRI is accurate in staging early rectal cancer and allows
identifying patients eligible for local excision.
Low rectal cancers (Fig. 1h) Tumour distance from the anal verge and intersphincteric plane status should
always be reported.
Beyond TME (Fig. 1i) High-resolution MRI defines the safe surgical planes. Every pelvic
compartment should be assessed for tumour spread.
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1 mm; T3b—1–5 mm beyond the muscularis propria; T3c—
5–15 mm beyond the muscularis propria; T3d—greater than
15 mm beyond the muscularis propria. All pathology studies
to date that have assessed the depth of spread have shown this
consistent relationship between extent of spread and prognosis
that is independent of other pathological findings [15, 17, 18].
The MERCURY study group confirmed that high-resolution
MRI measurement of depth of spread in millimetres showed
very precise agreement with corresponding pathology mea-
surements [19]. Furthermore the technique was able to differ-
entiate low-risk patients for local recurrence when tumour
spreads <5 mm into the mesorectum, negative mrCRM and
mrEMVI against poorer prognostic group of patients with
MRI-measured spread of tumour greater than 5 mm beyond
the muscularis (Fig. 1a) [20, 21]. Thus recording depth of
spread as Tsubstage gives greater prognostic information than
T and N stage when assessing rectal cancers using MRI.
Extent of Colon Cancer Beyond the Muscularis Propria
Stratification of colon cancer according to the extramural
spread beyond the muscularis propria has been proven to be
useful method for identifying high risk patients who could
benefit from neoadjuvant chemotherapy [22]. In a further
study of 94 patients, Dighe et al. reported computed tomogra-
phy (CT) to show 95 % sensitivity for differentiating T1/2 vs
T3/T4 colon tumour [23]. Accuracy of radiological staging in
50 patients randomised within the pilot phase of the Foxtrot
trial showed that 86 % (43 of 50) of tumours had adverse
features (inoperable tumour, positive lymph nodes, EMVI or
depth of invasion ≥5 mm) on pathological examination,
predicting a greater than 50 % recurrence risk at 3 years.
Preliminary results of the Foxtrot pilot has shown a likely
benefit from the use of preoperative chemotherapy: a greater
proportion of downstage tumours in pT0-T2 tumours (2 % in
surgical group vs 9 % in the preoperative CT group of locally
advanced colon cancers) and grade of tumour regression as
moderate or more from 2 % vs 31 % (p<0.0001) and a sig-
nificantly lower rate of CRM involvement 4 % versus 20 % in
favour of preoperative chemotherapy [24].
Circumferential Margin
Whatever the depth of tumour infiltration at the level of infil-
trating border assessment of the whole mesorectum is crucial-
ly important. Relationship of the tumour to the mesorectal
fascia should always be reported. A distance on MRI of less
than 1 mm to the mesorectal fascia was proven to predict
pCRM status (Fig. 1b) [25]; moreover mrCRM on baseline
scans was shown to be the most reliable prognostic factor for
5-year survival rates inMERCURY trial patients [26] and was
more important than T and N stage. For low rectal tumours
when almost no mesorectal fat serves as a boundary between
tumour and external sphincter/levator relationship of the tu-
mour to the intersphincteric plane is of the most importance
[5••]. Even T2 tumours with full thickness invasion of the
muscularis propria at the level of puborectalis sling should
be considered as circumferential margin (CRM) plane threat-
ened and for such patients a beyond TME plane extralevator
abdominoperineal excision (APE) should be performed to re-
duce the risk of positive resection margin.
The mesorectum should also be assessed for presence of
suspicious tumour deposits and extravascular tumour inva-
sion; for tumours arising at a height of <6 cm from the anal
verge, MRI detection of EMVI is independently associated
with a risk of pathologic CRM involvement [5••].
Lymph Nodes and Tumour Deposits
Published data suggest that morphological features such as
heterogeneous signal intensity and lymph node irregular cap-
sule border are accurate predictors of metastatic spread within
the nodes [27, 28]. However, if good quality TME surgery is
performed, nodal status seems to be of no prognostic impor-
tance for local recurrence [29, 30]. Shihab et al. reported that
MR-identified lymph nodes involving mesorectal fascia are
rarely a true cause of CRM infiltration on final pathology
and that involvement of the CRM only by lymph nodes is
uncommon [31].
Some nodular structures could represent vascular deposits,
a phenomenon that is difficult to assess on final histology as
absence of preserved nodular capsule preclude differentiating
malignant lymph node with affected capsule from tumour de-
posit. However, the latter predicts poorer prognosis [32, 33].
High-resolution MRI allows differentiating EMVI and nodu-
lar deposits along the infiltrated veins (Fig. 1c), which are
likely to represent venous deposits and could be classified
according to TNM 7th edition as N1c (extranodal tumour
deposits).
MR EMVI
Both MRI and histopathologic EMVI are strong predictors of
poor prognosis, particularly as a predictor of tumour
metastasising to the liver [30]. In multivariate analysis, the
presence of extramural vein invasion was significant for
DFS [34, 35••]. Changes in the EMVI status before and after
preoperative CRT from positive to negative improves the out-
come (DFS): a 3-year DFS 87.8 % and 9 % recurrence against
a 3-year DFS 45.8 % with 44 % recurrence (p<0.0001) in
those with no changes of EMVI status [36]. Survival out-
comes of patients with stage II and III disease found that
EMVI positive patients with stage II disease had similar out-
comes to those patients with stage III disease. Histology seems
to be less accurate in identifying EMVI especially after pre-
operative CRT [35••] and it has been stated by Royal College
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of Pathologists that EMVI is readily assessed byMRI (Fig. 1c)
and this should be communicated to pathologists so that they
can improve detection rates (especially following chemora-
diotherapy) [37].
Mucinous
Mucinous adenocarcinomas are associated with worse
disease-free and overall survival outcomes compared to non-
mucinous tumours and appear to be less sensitive to preoper-
ative CRT when compared with non-mucinous tumours [6,
38]. Histopathology reports usually contain data about tumour
differentiation; however, information about mucin presence
within the tumour before patient undergoes surgery could be
used in treatment decision-making. It has been shown that
MRI enables visualisation of the mucinous component within
the tumours, which appears as high signal intensity areas at the
site of the tumour (Fig. 1d) and is of prognostic importance.
Fig. 1 a An axial T2 image shows a semiannular tumour (before CRT)
infiltrating rectal wall at 5–11 o’clock position. The extramural spread
beyond the muscularis propria should be measured where it is the most
advanced at 9–10 o’clock (red line). bA distance of less than 1 mm to the
mesorectal fascia (yellow line) is considered as mrCRM+ve (red arrow).
c A nodular deposit (red arrow) discontiguous with the rectal wall is
located along the extramural veins (blue arrow). The extramural veins
are also expanded and have intermediate signal within them—features of
EMVI. d High signal intensity areas (red arrows) within the tumour are
suggestive of mucinous content. e Low-density fibrosis is noted at the
level of the treated tumour (red arrows) after CRT (the same patient as at
Fig. 1a). f The same level of tumour as in Fig. 1e. High b value (1000)
DW image shows evidence of restricted diffusion (red arrow); despite
these findings, the patient has been enrolled in the deferral of surgery trial
and is disease free for 3 years. g High-resolution axial MRI shows a
sessile lesion infiltrating rectal wall at 4–6 o’clock position. A high signal
intensity line (red arrow) is visible between the tumour and muscularis
propria, which represent partially preserved submucosal layer. h A low
rectal tumour confined to the part thickness of muscularis propria, indi-
cating that the intersphincteric or mesorectal planes are safe. i Pelvic
compartments are marked on these two high-resolution MR images
(L—left compartment, central above the peritoneal reflection (PR), cen-
tral below the PR, posterior, infralevator)
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Moreover, MRI pre-treatment diagnosis of mucinous tumour
can be made more readily than preoperative histopathologic
biopsy [39].
Post CRT Tumour Response Assessment
Standard T2
MRRECISTand Volumetric Analysis Different MRI tech-
niques have been proposed as a tool for tumour response as-
sessment; one of these is modified mr RECISTwhich is based
on objective measurements of the change in craniocaudal
length of measurable disease. According to new guidelines
to evaluate the response to treatment in solid tumours, at least
30 % reduction rate should be considered as good or
favourable response [40]. However, there is no established
threshold for defining response in a luminal organ such as
the rectum. MR volumetric analysis is another technique that
was suggested to be a reliable tool for tumour response assess-
ment [41, 42]. However there is again no published precise/
accurate cutoff values of tumour volume reduction to predict
favourable response or outcomes by comparing three dimen-
sional tumour volumes of the tumour on pre- and post-CRT
scans.
MR TRG An MR regression-grading system based on the
principles of the modified Mandard TRG system has been
proposed for assessment of tumour response in rectal cancer
classifying post-treatment changes. This divides response into
five categories based on the proportion of intermediate tumour
signal intensity versus low fibrosis signal intensity within the
treated tumour (TRG1—total regression of the tumour which
displays as liner low signal intensity scar on high resolution
MRI scans; TRG2—low density fibrosis with no evident of
macroscopic intermediate signal intensity within it (Fig. 1e);
TRG3—MRI shows predominant fibrosis signal with some
intermediate signal intensity areas; TRG4/5—predominantly
intermediate signal intensity, minor regression, minimal fibro-
sis) [43]. In the retrospective CORE trial with 11 participant
centres, different tumour regression parameters were assessed.
Using binary logistic regression analysis it has been shown
that only ymrT and MRTRG are significantly corresponds to
final histology results compared to mrRECISTand mrVolume
regression analysis [44]. Furthermore, MRTRGwas shown to
be an independent prognostic factor of disease-free survival
[12].
Diffusion-Weighted Imaging
Published data suggests that an objectively useful role of dif-
fusion imaging for primary rectal cancer assessment and
restaging after chemoradiotherapy has not yet been found.
Residual disease is expected when hyperintense signal is
visualised on high b value diffusion-weighted images at the
site of treated tumour (Fig. 1f) [45, 46]. However, there is no
evidence showing that this technique was validated against
other existing parameters and patient outcomes. It has been
proposed that combined DWI and T2 WI could increase MRI
accuracy for identifying complete responders; however, the
results only significant for those radiologists with not much
of experience in reading rectal MRIs [45]. Whereas inter-
observer agreement for MRTRG was shown to be 0.8 regard-
less of experience suggesting this method to be reproducible
[47]. Furthermore incorporating MR TRG into assessment of
surgical plane safety in the low rectal cancer after chemora-
diotherapy enabled good prediction of likely clear margins
[5••].
Defining Surgical Planes
Early Rectal Cancer
Staging of early rectal tumours could be a challenge, mistakes
in image interpretation lead to over or undertreatment of pa-
tients, who should on the contrary benefit from being diag-
nosed on the early stage of tumour invasion. For tumours less
than T1 sm3 without any poor prognostic features (such as
lymph nodes or extramural venous invasion) local excision
could be considered as the main treatment option.
Since the 1990s, endorectal ultrasound (ERUS) has
been considered as the best diagnostic modality for ear-
ly rectal cancer, and accuracy rates were reported to be
as high as 90 % [48–50]. However, more resent data
suggests the contrary; Garcia-Aguilar et al. reported
ERUS to be an inaccurate (unreliable) tool for T1 and
T2 early rectal cancer differentiation (59 %), showing
that recurrence and survival rates were not influenced
by the fact patients having or not having preoperative
ERUS [51]. Sailer M. et al. proposed that ERUS is of
no help in the assessment of T2 carcinomas [52].
Accuracy of ERUS in detection lymph node metastases
ranges from 60 to 80 %, so that preoperative ERUS
staging cannot exclude node positive status [53, 54].
In our study where treatment decision was made by
clinical not mr-assessment [55], MRI accuracy of iden-
tifying patients eligible for organ-preserving surgery (tu-
mours less than T1sm3) was 73 %. If the decision had
been made based on MRI, T stage TME surgery vs
local excision could have been offered in significantly
fewer patients—14 % (6/43) (p< 0.01). The presence of
at least 1 mm of submucosal layer identified as high
signal intensity line between the tumour-advancing edge
and muscularis suggest that LE is safe and feasible to
perform (Fig. 1g).
166 Curr Colorectal Cancer Rep (2016) 12:162–169
Low Rectal Tumours
Distal tumour margin lower or at the level of 6 cm from the
anal verge indicates a low-lying tumour in the portion of the
mesorectum that tapers and is thus at higher risk of margin
involvement during TME plane surgery. Recurrence free sur-
vival improves with an increased likelihood of receiving the
appropriate treatment when low rectal tumours are preopera-
tively staged by MRI [56, 57]. High-resolution MRI enables
staging and assessment of the surgical planes in patients with
low rectal cancer when the relationship to the intersphincteric
plane, external sphincter and levators are of the main
concerns.
In low rectal tumours confined to the submucosal layer/part
thickness of muscularis propria, the intersphincteric or
mesorectal planes are safe and intersphincteric APE or ultra
low TME is possible (Fig. 1h).
When tumour extends through the full thickness of the
muscularis propria, into the intersphincteric plane or into the
external sphincter, full clearance is unlikely, and therefore an
extralevator APE is indicated for radial clearance.
Beyond TME
In patients with CRM involvement, R0 resection can only be
achieved if surgical planes are extended beyond the TME
plane, and the radiologist plays a fundamental role in both
identifying these cases and correctly assessing the surgical
planes required for histological clearance. High-resolution
T2-WI MR allows identifying surgical planes and indicates
when extralevator abdominoperineal resections (ELAPE) and
exenterative surgery could potentially be performed [58]. On
multivariate analysis, only a positive resection margin was a
significant predictor of reduced local recurrence free survival
(hazard ratio, 5.48; p=0.002) [59].
A useful system is to divide the pelvis into six surgical
compartments (central above peritoneal reflection: any struc-
ture above the peritoneal reflection/uterus; anteriorly below
peritoneal reflection: bladder/upper vagina/ovaries/prostate/
seminal vesicles/urethra; posteriorly: bony cortex/periosteum
S1-5, coccyx/presacral fascia (S1-5)/sciatic nerve/sacral nerve
branches (S1/2); laterally: pelvic fascia/pelvic sidewall/inter-
nal/external iliac vessels/sacrotuberous/sacrospinous liga-
ments/piriformis/obturator internus muscles; infralevator:
Levator muscles/sphincter complex; anterior urogenital trian-
gle/perineum: vaginal introitus/urethra/retropubic space) [58]
(Fig. 1i).
Conclusion
Treatment decisions are no longer made by a single specialist
but a colorectal unit team, when pre-treatment tumour spread
assessment drives the type of treatment to be chosen. Imaging
plays a pivotal role in guiding the treatment management.
Surgeons push forward radiologists to improve staging accu-
racy of most accepted tumour spread criteria such as T and N;
however, the paradigm of tumour spread prognostic factors
has shifted and new imaging biomarkers are emerging into
the routine radiological practise.
Such tumour spread markers as EMVI, relationship to the
mesorectal fascia and intersphincteric plane (CRM status),
presence of mucin component within the tumour have a great-
er influence on patient outcomes than T and stage and there-
fore should now be factored into treatment decisions.
Imaging enables better stratification of patients in risk
groups for local and distal failure, helps to clarify safe surgical
planes, identifies those patients who could potentially benefit
from preoperative treatment and ultimately could identify
those patients for whom surgery may be safely omitted of
deferred.
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